Key result
Remdesivir shows modest antiviral activity against Sabin-like poliovirus types 1 and 3 in HeLa cells.
Why the study?
Complete poliovirus eradication requires managing chronic excreters and controlling outbreaks, and RdRp inhibitors represent promising candidates.
Remdesivir, Favipiravir, and Ribavirin show potential in vitro antiviral activity against poliovirus.
Modest in vitro activity offers no clinical implications for poliovirus; leaves open targeted animal studies.
Complete poliovirus eradication requires managing chronic excreters and controlling potential outbreaks. RNA-dependent RNA Polymerase (RdRp) inhibitors represent promising candidates for this purpose. The antiviral activities of Remdesivir, Favipiravir, and Ribavirin against Sabin-like poliovirus types 1 (SL1) and 3 (SL3) were evaluated in HeLa cells individually and in combination. Antiviral effects were measured by cytopathic effect inhibition, MTT assay, and qRT-PCR. Drug-drug interactions were analyzed using Synergy Finder Plus. Molecular docking was performed to evaluate RdRp binding affinity. Remdesivir demonstrated the modest activity with low EC
No takes yet. Share an insight, caveat, or question.
Soheili et al. (2026) studied Poliovirus. Remdesivir, Favipiravir, and Ribavirin was evaluated on Antiviral effects measured by cytopathic effect inhibition, MTT assay, and qRT-PCR. Remdesivir demonstrated modest antiviral activity against Sabin-like poliovirus types 1 and 3 in HeLa cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: